Vor Biopharma Inc. (VOR)

Nasdaq: VOR · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2020

Full chart Alerts Compare

Grade4.0

◀ Past 3.5● Present 1.7▶ Future 6.4

7 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Who owns Vor Biopharma Inc.

As filed with the SEC

Holders of 5% or more

RA Capital Management, L.P. holds 19.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Jul 21, 2026 says.

Directors and officers

report now, of 31 people on the record since 2021. Their holdings as a group are not read here.

Institutions as a whole

n/a

The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.

Holders of 5% or moreshare of the class, as filed

RA Capital Management, L.P.

SCHEDULE 13D/A · filed Jul 21, 2026 · Common Stock, par value $0.0001 per share · 19.9% in Apr 21, 2026

19.9%

Reprogrammed Interchange LLC

SCHEDULE 13D/A · filed Oct 17, 2025 · Common Stock, par value $.0001 per share · 18.6% in Oct 16, 2025

17.6%

Fmr LLC

SCHEDULE 13G/A · filed Aug 7, 2026 · COMMON STOCK · 9.1% in Aug 6, 2026

12%

Chen Yu

SCHEDULE 13G · filed Apr 1, 2026 · Common Stock, par value $0.0001 per share

10.5%

ForGrowth III PA B.V.

SCHEDULE 13D · filed Dec 23, 2025 · Common Stock, $0.0001 par value per share · 9.99% in Sep 23, 2025

9.99%

Venrock Healthcare Capital Partners III, L.P.

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 9.9% in May 15, 2026

9.9%

Verve Capital Limited

SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.0001 par value per share · 9.3% in May 15, 2026

6.3%

Blackrock, Inc.

SCHEDULE 13G · filed Jul 30, 2026 · Common Stock

5.7%

Paradigm BioCapital Advisors LP

SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 8.6% in Nov 18, 2025

under 5%

Frazier Life Sciences Public Fund, L.P.

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.8% in Dec 19, 2025

under 5%

Andrew J. Schwab

SCHEDULE 13D/A · filed Jul 9, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%

under 5%

Great Point Partners, LLC

SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.63% in Dec 17, 2025

under 5%

Qiming Venture Partners VIII-HC, L.P.

SCHEDULE 13G/A · filed May 6, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 2.8% in Feb 13, 2026

under 5%

What VOR reports owning in othersstakes of 5% or more, and other ties

Vor Biopharma Inc. reports no stake in another company in the record.

Insider tradesForm 4

16sales

0purchases

0sales on a scheduled plan

3people selling

$49.4Msold, in dollars

$0bought, in dollars

Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.

By calendar yearSoldBought

21242526

2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.

People who traded in the window3 of 44 on the roster

Person	Role as filed	Sales	Sold	Bought
Ra Capital Management, L.P.	director	5	$22.1M	$0
Kolchinsky Peter	director	5	$14.5M	$0
Shah Rajeev M.	director	6	$12.8M	$0

SI Assistanton VOR · research, not advice